Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges

NovartisSandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators in the field of digital technology to submit inspirational ideas with the potential to complement - or even positively disrupt - established approaches to driving access to healthcare.

#SandozHACk opens for entries, closing on November 30, 2018.

Universal access to healthcare is still arguably the largest unmet medical need and, while great strides continue to be made globally, access challenges vary hugely across geographies and communities. Therefore, a major step towards improving healthcare access globally is to identify and understand the specific needs of local communities.

"There are still two billion people in this world not getting the medicines they need. This is why we are launching Sandoz HACk as we aim to inspire and embrace the brave and innovative thinking of entrepreneurs and visionaries to improve access to healthcare around the world", said Richard Francis, Division Head and CEO of Sandoz.

Francis added: "Building on the inaugural Sandoz HACk, this year we are broadening the competition to anyone, anywhere, with an idea that uses digital technology to help address a local healthcare access challenge. By collaborating, we hope to create ambitious-yet-practical digital solutions that, with scale, could have a significant impact on people's lives."

Digital innovation promises cost-effective and practical solutions with the power to transform access. Last year, Sandoz HACk focused on m-health (mobile health). This year's theme is 'Leveraging Digital Technologies to Solve Healthcare Access Challenges': encouraging ideas that can drive patient access or help healthcare providers to reach more people.

Three shortlisted entrants, to be announced in January 2019, will receive support from Sandoz experts to develop their ideas and transform potential into real impact. Our three finalists will travel to the world's leading forward-focused gathering of creative minds, South by Southwest (SXSW; Austin, Texas) in March 2019, to explore, network and discover the latest innovative trends. Following in-person selection, one winner will be chosen and awarded seed funding and support from Sandoz, to help bring their idea to life.

For more details on how to enter the competition and terms and conditions, please visit: https://www.sandoz.com/making-access-happen/sandoz-hack

About Sandoz HACk

As the global leader in biosimilars, generic antibiotics and generic oncology medicines, Sandoz aims to play a leading role in making access happen for people around the world. Through Sandoz HACk we will use our expertise to bring access ideas in these areas, and beyond, to life. We believe that small ideas can spark big change and that, together, we can co-create ambitious-yet-practical solutions that break down access barriers around the world.

About Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...